FDA Approves Afami-cel

Sherry Shen, MD, discussed the multi-faceted challenges patients with breast cancer experience regarding weight gain during and after active treatment. From the immediate fluid retention and steroid use associated with chemotherapy to the long-term metabolic impacts of endocrine therapy and treatment-induced menopause, patients frequently see significant shifts in fat distribution and metabolic health.

Kim Stravers is a certified end-of-life doula and educator with the International End of Life Doula Association (INELDA), with additional proficiency through the National End of Life Doula Alliance (NEDA). Based in the Phoenix, Arizona area, she volunteers with a local hospice organization, has presented at Grand Rounds for the Palliative Care Department at Mayo Clinic Arizona, and provides private doula services to patients with serious illness and their circles of care.

Background Women with metastatic breast cancer form a very heterogeneous population. Current breast cancer detection and systemic treatment options have resulted in longer survival for MBC patients of all molecular subtypes. The optimal treatment regarding the use of metastasis-directed therapy (MDT) and local-regional therapy for patients with asymptomatic lesions remains controversial.